Keywords: |
controlled study; major clinical study; clinical trial; review; fluorouracil; cancer combination chemotherapy; dose response; drug efficacy; drug safety; paclitaxel; cancer adjuvant therapy; chemotherapy, adjuvant; cancer staging; lymph node metastasis; antineoplastic agent; neoplasms; controlled clinical trial; phase 2 clinical trial; anemia; bone marrow suppression; neuropathy; randomized controlled trial; antineoplastic combined chemotherapy protocols; antineoplastic agents, phytogenic; cyclophosphamide; docetaxel; febrile neutropenia; hyperglycemia; drug mechanism; cardiotoxicity; breast carcinoma; epirubicin; taxoids; phase 3 clinical trial; taxane derivative; trastuzumab; granulocyte colony stimulating factor; clinical trials; humans; human; female; priority journal
|